JPMorgan Chase & Co. Lowers Stock Position in LivaNova PLC (NASDAQ:LIVN)

JPMorgan Chase & Co. lessened its stake in LivaNova PLC (NASDAQ:LIVN) by 3.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 198,107 shares of the company’s stock after selling 7,345 shares during the period. JPMorgan Chase & Co. owned approximately 0.36% of LivaNova worth $10,409,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in LIVN. Arizona State Retirement System grew its position in LivaNova by 2.0% in the second quarter. Arizona State Retirement System now owns 15,104 shares of the company’s stock worth $828,000 after acquiring an additional 299 shares in the last quarter. Texas Permanent School Fund Corp boosted its holdings in shares of LivaNova by 4.1% in the 2nd quarter. Texas Permanent School Fund Corp now owns 49,086 shares of the company’s stock worth $2,691,000 after purchasing an additional 1,939 shares in the last quarter. WINTON GROUP Ltd increased its position in shares of LivaNova by 137.0% during the 2nd quarter. WINTON GROUP Ltd now owns 17,067 shares of the company’s stock valued at $936,000 after purchasing an additional 9,865 shares during the last quarter. Primecap Management Co. CA raised its holdings in shares of LivaNova by 0.7% during the 2nd quarter. Primecap Management Co. CA now owns 5,981,200 shares of the company’s stock valued at $327,889,000 after buying an additional 44,049 shares in the last quarter. Finally, Intech Investment Management LLC bought a new stake in LivaNova in the 2nd quarter worth approximately $481,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Stock Down 2.9 %

NASDAQ LIVN opened at $46.66 on Monday. LivaNova PLC has a 1 year low of $43.15 and a 1 year high of $64.47. The stock has a market capitalization of $2.53 billion, a PE ratio of 111.10 and a beta of 1.01. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The business’s 50-day moving average is $49.82 and its 200 day moving average is $50.31.

Analyst Ratings Changes

A number of research analysts have commented on the stock. StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 25th. Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. The Goldman Sachs Group initiated coverage on shares of LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 price objective on shares of LivaNova in a research note on Monday, November 25th. Finally, Mizuho lowered their target price on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $69.17.

Insiders Place Their Bets

In related news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the transaction, the director now owns 7,522 shares in the company, valued at $383,546.78. The trade was a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.27% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.